Prions

Fields Virology: Sixth Edition

Volumn 1, Issue , 2013, Pages

  Prusiner, Stanley B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84974678558     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (452)

1. Abid K, Morales R, Soto C. Cellular factors implicated in prion replication. FEBS Lett 2010;584:2409-2414.
2. Adrover M, Pauwels K, Prigent S, et al. Prion fibrillization is mediated by a native structural element that comprises helices H2 and H3. J Biol Chem 2010;285:21004-21012.
3. Alper T, Cramp WA, Haig DA, et al. Does the agent of scrapie replicate without nucleic acid? Nature 1967;214:764-766.
4. Alpers MP. A history of kuru. P N G Med J 2007;50:10-19.
5. Alpers MP. Kuru: implications of its transmissibility for the interpretation of its changing epidemiological pattern. In: Bailey OT, Smith DE, eds. The Central Nervous System: Some Experimental Models of Neurological Diseases. Baltimore: Williams and Wilkins Company; 1968:234-251.
6. Alter M, Kahana E. Creutzfeldt-Jakob disease among Libyan Jews in Israel. Science 1976;192:428.
7. Anderson RM, Donnelly CA, Ferguson NM, et al. Transmission dynamics and epidemiology of BSE in British cattle. Nature 1996;382:779-788.
8. Anfinsen CB. Principles that govern the folding of protein chains. Science 1973;181:223-230.
9. Angot E, Steiner JA, Hansen C, et al. Are synucleinopathies prion-like disorders? Lancet Neurol 2010;9:1128-1138.
10. Antonyuk SV, Trevitt CR, Strange RW, et al. Crystal structure of human prion protein bound to a therapeutic antibody. Proc Natl Acad Sci U S A 2009;106:2554-2558.
11. Apostol MI, Sawaya MR, Cascio D, et al. Crystallographic studies of prion protein (PrP) segments suggest how structural changes encoded by polymorphism at residue 129 modulate susceptibility to human prion disease. J Biol Chem 2010;285:29671-29675.
12. Apostol MI, Wiltzius JJ, Sawaya MR, et al. Atomic structures suggest determinants of transmission barriers in mammalian prion disease. Biochemistry 2011;50:2456-2463.
13. Aronoff-Spencer E, Burns CS, Avdievich NI, et al. Identification of the Cu2+ binding sites in the N-terminal domain of the prion protein by EPR and CD spectroscopy. Biochemistry 2000;39:13760-13771.
14. Asante EA, Linehan JM, Desbruslais M, et al. BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J 2002;21:6358-6366.
15. Ayers JI, Schutt CR, Shikiya RA, et al. The strain-encoded relationship between PrP replication, stability and processing in neurons is predictive of the incubation period of disease. PLoS Pathog 2011;7:e1001317.
16. Baker HF, Ridley RM, Wells GAH. Experimental transmission of BSE and scrapie to the common marmoset. Vet Rec 1993;132:403-406.
17. Barret A, Tagliavini F, Forloni G, et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003;77:8462-8469.
18. Barria MA, Mukherjee A, Gonzalez-Romero D, et al. De novo generation of infectious prions in vitro produces a new disease phenotype. PLoS Pathog 2009;5:e1000421.
19. Bartels T, Choi JG, Selkoe DJ. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011;477:107-110.
20. Bellinger-Kawahara CG, Kempner E, Groth DF, et al. Scrapie prion liposomes and rods exhibit target sizes of 55,000 Da. Virology 1988;164:537-541.
21. Bellon A, Seyfert-Brandt W, Lang W, et al. Improved conformation-dependent immunoassay: suitability for human prion detection with enhanced sensitivity. J Gen Virol 2003;84:1921-1925.
22. Bertho G, Bouvier G, Hoa GH, et al. The key-role of tyrosine 155 in the mechanism of prion transconformation as highlighted by a study of sheep mutant peptides. Peptides 2008;29:1073-1084.
23. Bessen RA, Kocisko DA, Raymond GJ, et al. Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature 1995;375:698-700.
24. Bessen RA, Marsh RF. Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent. J Virol 1992;66:2096-2101.
25. Bessen RA, Marsh RF. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J Virol 1994;68:7859-7868.
26. Bessen RA, Marsh RF. Identification of two biologically distinct strains of transmissible mink encephalopathy in hamsters. J Gen Virol 1992;73:329-334.
27. Biljan I, Ilc G, Giachin G, et al. Toward the molecular basis of inherited prion diseases: NMR structure of the human prion protein with V210I mutation. J Mol Biol 2011;412:660-673.
28. Biverstahl H, Andersson A, Graslund A, et al. NMR solution structure and membrane interaction of the N-terminal sequence (1-30) of the bovine prion protein. Biochemistry 2004;43:14940-14947.
29. Borchelt DR, Scott M, Taraboulos A, et al. Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J Cell Biol 1990;110:743-752.
30. Bosque PJ, Ryou C, Telling G, et al. Prions in skeletal muscle. Proc Natl Acad Sci U S A 2002;99:3812-3817.
31. Bousset L, Belrhali H, Janin J, et al. Structure of the globular region of the prion protein Ure2 from the yeast Saccharomyces cerevisiae. Structure 2001;9:39-46.
32. Bousset L, Belrhali H, Melki R, et al. Crystal structures of the yeast prion Ure2p functional region in complex with glutathione and related compounds. Biochemistry 2001;40:13564-13573.
33. Bouzamondo-Bernstein E, Hopkins SD, Spilman P, et al. The neurodegeneration sequence in prion diseases: Evidence from functional, morphological and ultrastructural studies of the GABAergic system. J Neuropathol Exp Neurol 2004;63:882-899.
34. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259.
35. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995;16:271-284.
36. Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology 2008;70:1916-1925.
37. Brandner S, Isenmann S, Raeber A, et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 1996;379:339-343.
38. Brion JP, Couck AM, Passareiro E, et al. Neurofibrillary tangles of Alzheimer's disease: an immunohistochemical study. J Submicrosc Cytol 1985;17:89-96.
39. Brown P. Blood infectivity, processing and screening tests in transmissible spongiform encephalopathy. Vox Sang 2005;89:63-70.
40. Browning SR, Mason GL, Seward T, et al. Transmission of prions from mule deer and elk with chronic wasting disease to transgenic mice expressing cervid PrP. J Virol 2004;78:13345-13350.
41. Bruce ME, Dickinson AG. Biological evidence that the scrapie agent has an independent genome. J Gen Virol 1987;68:79-89.
42. Bruce ME, Dickinson AG. Genetic control of amyloid plaque production and incubation period in scrapie-infected mice. J Neuropathol Exp Neurol 1985;44:285-294.
43. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997;389:498-501.
44. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 2010;11:301-307.
45. Büeler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell 1993;73:1339-1347.
46. Büeler H, Fisher M, Lang Y, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992;356:577-582.
47. Büeler H, Raeber A, Sailer A, et al. High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med 1994;1:19-30.
48. Burns CS, Aronoff-Spencer E, Dunham CM, et al. Molecular features of the copper binding sites in the octarepeat domain of the prion protein. Biochemistry 2002;41:3991-4001.
49. Buschmann A, Pfaff E, Reifenberg K, et al. Detection of cattle-derived BSE prions using transgenic mice overexpressing bovine PrPC. Arch Virol Suppl 2000;16:75-86.
50. Calzolai L, Lysek DA, Güntert P, et al. NMR structures of three single-residue variants of the human prion protein. Proc Natl Acad Sci U S A 2000;97:8340-8345.
51. Calzolai L, Lysek DA, Perez DR, et al. Prion protein NMR structures of chickens, turtles, and frogs. Proc Natl Acad Sci U S A 2005;102:651-655.
52. Calzolai L, Zahn R. Influence of pH on NMR structure and stability of the human prion protein globular domain. J Biol Chem 2003;278:35592-35596.
53. Carlson GA, Ebeling C, Yang S-L, et al. Prion isolate specified allotypic interactions between the cellular and scrapie prion proteins in congenic and transgenic mice. Proc Natl Acad Sci U S A 1994;91:5690-5694.
54. Carlson GA, Kingsbury DT, Goodman PA, et al. Linkage of prion protein and scrapie incubation time genes. Cell 1986;46:503-511.
55. Castilla J, Gonzalez-Romero D, Saa P, et al. Crossing the species barrier by PrPSc replication in vitro generates unique infectious prions. Cell 2008;134:757-768.
56. Castilla J, Saa P, Hetz C, et al. In vitro generation of infectious scrapie prions. Cell 2005;121:195-206.
57. Cathcart ES, Rodgers OG, Cohen AS. Amyloid-inducing factor and immunological unresponsiveness. Ann Rheum Dis 1972;31:303-307.
58. Caughey B, Kocisko DA, Raymond GJ, et al. Aggregates of scrapie-associated prion protein induce the cell-free conversion of protease-sensitive prion protein to the protease-resistant state. Chem Biol 1995;2:807-817.
59. Caughey B, Race RE. Potent inhibition of scrapie-associated PrP accumulation by Congo red. J Neurochem 1992;59:768-771.
60. Caughey B, Race RE, Ernst D, et al. Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol 1989;63:175-181.
61. Caughey B, Raymond GJ. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease-and phospholipase-sensitive. J Biol Chem 1991;266:18217-18223.
62. Caughey B, Raymond GJ, Kocisko DA, et al. Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. J Virol 1997;71:4107-4110.
63. Caughey BW, Dong A, Bhat KS, et al. Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry 1991;30:7672-7680.
64. Centers for Disease Control. Surveillance for Creutzfeldt-Jakob Disease-United States. MMWR Morb Mortal Wkly Rep 1996;45:665-668.
65. Chapman J, Ben-Israel J, Goldhammer Y, et al. The risk of developing Creutzfeldt-Jakob disease in subjects with the PRNP gene codon 200 point mutation. Neurology 1994;44:1683-1686.
66. Chen S, Mange A, Dong L, et al. Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival. Mol Cell Neurosci 2003;22:227-233.
67. Chesebro B, Race B, Meade-White K, et al. Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring. PLoS Pathog 2010;6:e1000800.
68. Chesebro B, Race R, Wehrly K, et al. Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature 1985;315:331-333.
69. Chesebro B, Trifilo M, Race R, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 2005;308:1435-1439.
70. Chien P, Weissman JS, DePace AH. Emerging principles of conformation-based prion inheritance. Annu Rev Biochem 2004;73:617-656.
71. Chiesa R, Piccardo P, Quaglio E, et al. Molecular distinction between pathogenic and infectious properties of the prion protein. J Virol 2003;77:7611-7622.
72. Christen B, Hornemann S, Damberger FF, et al. Prion protein NMR structure from tammar wallaby (Macropus eugenii) shows that the beta2-alpha2 loop is modulated by long-range sequence effects. J Mol Biol 2009;389:833-845.
73. Christen B, Perez DR, Hornemann S, et al. NMR structure of the bank vole prion protein at 20 degrees C contains a structured loop of residues 165-171. J Mol Biol 2008;383:306-312.
74. Chung E, Prelli F, Dealler S, et al. Styryl-based and tricyclic compounds as potential anti-prion agents. PLoS One 2011;6:e24844.
75. Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009;11:909-913.
76. Clousard C, Beaudry P, Elsen JM, et al. Different allelic effects of the codons 136 and 171 of the prion protein gene in sheep with natural scrapie. J Gen Virol 1995;76:2097-2101.
77. Colby DW, Giles K, Legname G, et al. Design and construction of diverse mammalian prion strains. Proc Natl Acad Sci U S A 2009;106:20417-20422.
78. Colby DW, Prusiner SB. De novo generation of prions. Nat Rev Microbiol 2011;9:771-777.
79. Colby DW, Wain R, Baskakov IV, et al. Protease-sensitive synthetic prions. PLoS Pathog 2010;6:e1000736.
80. Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009;8:334-344.
81. Collinge J, Sidle KCL, Meads J, et al. Molecular analysis of prion strain variation and the aetiology of "new variant" CJD. Nature 1996;383:685-690.
82. Collins SJ, Lewis V, Brazier M, et al. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002;52:503-506.
83. Corsellis JA, Bruton CJ, Freeman-Browne D. The aftermath of boxing. Psychol Med 1973;3:270-303.
84. Corsellis JAN. Posttraumatic dementia. Aging 1978;7:125-133.
85. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
86. Cousens SN, Harries-Jones R, Knight R, et al. Geographical distribution of cases of Creutzfeldt-Jakob disease in England and Wales 1970-84. J Neurol Neurosurg Psychiatry 1990;53:459-465.
87. Criado JR, Sanchez-Alavez M, Conti B, et al. Mice devoid of prion protein have cognitive deficits that are rescued by reconstitution of PrP in neurons. Neurobiol Dis 2005;19:255-265.
88. Cushman M, Johnson BS, King OD, et al. Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci 2010;123:1191-1201.
89. Daude N, Lehmann S, Harris DA. Identification of intermediate steps in the conversion of a mutant prion protein to a scrapie-like form in cultured cells. J Biol Chem 1997;272:11604-11612.
90. DeArmond SJ, Ironside JW, Bouzamondo-Bernstein E, et al. Neuropathology of prion diseases. In: Prusiner SB, ed. Prion Biology and Diseases. 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2004:777-856.
91. DeArmond SJ, Kretzschmar HA, Prusiner SB. Prion diseases. In: Graham DI, Lantos PL, eds. Greenfield's Neuropathology. 7th ed. London: Hodder Arnold; 2002:273-323.
92. DeArmond SJ, McKinley MP, Barry RA, et al. Identification of prion amyloid filaments in scrapie-infected brain. Cell 1985;41:221-235.
93. Deleault NR, Harris BT, Rees JR, et al. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A 2007;104:9741-9746.
94. Deleault NR, Kascsak R, Geoghegan JC, et al. Species-dependent differences in cofactor utilization for formation of the protease-resistant prion protein in vitro. Biochemistry 2010;49:3928-3934.
95. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009;106:13010-13015.
96. Diaz-Espinoza R, Soto C. Generation of prions in vitro and the protein-only hypothesis. Prion 2010;4:1-7.
97. Dickinson AG, Fraser H, Meikle VMH, et al. Competition between different scrapie agents in mice. Nat New Biol 1972;237:244-245.
98. Dickinson AG, Meikle VMH, Fraser H. Identification of a gene which controls the incubation period of some strains of scrapie agent in mice. J Comp Pathol 1968;78:293-299.
99. Dickinson AG, Young GB, Stamp JT, et al. An analysis of natural scrapie in Suffolk sheep. Heredity 1965;20:485-503.
100. Diener TO, McKinley MP, Prusiner SB. Viroids and prions. Proc Natl Acad Sci U S A 1982;79:5220-5224.
101. Doh-ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000;74:4894-4897.
102. Donne DG, Viles JH, Groth D, et al. Structure of the recombinant full-length hamster prion protein PrP(29-231): the N terminus is highly flexible. Proc Natl Acad Sci U S A 1997;94:13452-13457.
103. Edgeworth JA, Farmer M, Sicilia A, et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet 2011;377:487-493.
104. Eghiaian F, Grosclaude J, Lesceu S, et al. Insight into the PrPC->PrPSc conversion from the structures of antibody-bound ovine prion scrapie-susceptibility variants. Proc Natl Acad Sci U S A 2004;101:10254-10259.
105. Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A 2001;98:9295-9299.
106. Endo T, Groth D, Prusiner SB, et al. Diversity of oligosaccharide structures linked to asparagines of the scrapie prion protein. Biochemistry 1989;28:8380-8388.
107. Fagge T, Barclay GR, Macgregor I, et al. Variation in concentration of prion protein in the peripheral blood of patients with variant and sporadic Creutzfeldt-Jakob disease detected by dissociation enhanced lanthanide fluoroimmunoassay and flow cytometry. Transfusion 2005;45:504-513.
108. Fichet G, Comoy E, Duval C, et al. Novel methods for disinfection of prion-contaminated medical devices. Lancet 2004;364:521-526.
109. Fink JK, Peacock ML, Warren JT, et al. Detecting prion protein gene mutations by denaturing gradient gel electrophoresis. Hum Mutat 1994;4:42-50.
110. Fischer M, Rülicke T, Raeber A, et al. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J 1996;15:1255-1264.
111. Flint EB, Suslick KS. The temperature of cavitation. Science 1991;253:1397-1399.
112. Forloni G, Angeretti N, Chiesa R, et al. Neurotoxicity of a prion protein fragment. Nature 1993;362:543-546.
113. Foster J, Goldmann W, Parnham D, et al. Partial dissociation of PrPSc deposition and vacuolation in the brains of scrapie and BSE experimentally affected goats. J Gen Virol 2001;82:267-273.
114. Fraser H, Bruce ME, Chree A, et al. Transmission of bovine spongiform encephalopathy and scrapie to mice. J Gen Virol 1992;73:1891-1897.
115. Fraser H, Dickinson AG. Scrapie in mice. Agent-strain differences in the distribution and intensity of grey matter vacuolation. J Comp Pathol 1973;83:29-40.
116. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 2009;284:12845-12852.
117. Furukawa Y, Kaneko K, Matsumoto G, et al. Cross-seeding fibrillation of Q/N-rich proteins offers new pathomechanism of polyglutamine diseases. J Neurosci 2009;29:5153-5162.
118. Gabizon R, McKinley MP, Groth D, et al. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc Natl Acad Sci U S A 1988;85:6617-6621.
119. Gabizon R, Rosenmann H, Meiner Z, et al. Mutation and polymorphism of the prion protein gene in Libyan Jews with Creutzfeldt-Jakob disease (CJD). Am J Hum Genet 1993;53:828-835.
120. Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science 1977;197:943-960.
121. Gambetti P, Dong Z, Yuan J, et al. A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol 2008;63:697-708.
122. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995;373:523-527.
123. Gasset M, Baldwin MA, Fletterick RJ, et al. Perturbation of the secondary structure of the scrapie prion protein under conditions that alter infectivity. Proc Natl Acad Sci U S A 1993;90:1-5.
124. Gayrard V, Picard-Hagen N, Viguie C, et al. A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapie. Br J Pharmacol 2005;144:386-393.
125. Geschwind MD, Martindale J, Miller D, et al. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 2003;60:813-816.
126. Ghaemmaghami S, Ahn M, Lessard P, et al. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog 2009;5:e1000673.
127. Ghaemmaghami S, May BCH, Renslo AR, et al. Discovery of 2-aminothiazoles as potent antiprion compounds. J Virol 2010;84:3408-3412.
128. Ghaemmaghami S, Ullman J, Ahn M, et al. Chemical induction of misfolded prion protein conformers in cell culture. J Biol Chem 2010;285:10415-10423.
129. Ghaemmaghami S, Watts JC, Nguyen H-O, et al. Conformational transformation and selection of synthetic prion strains. J Mol Biol 2011;413:527-542.
130. Ghani AC, Ferguson NM, Donnelly CA, et al. Predicted vCJD mortality in Great Britain. Nature 2000;406:583-584.
131. Ghetti B, Piccardo P, Bugiani O, et al. Hereditary prion protein amyloidosis. In: Brown DR, ed. Neurodegeneration and Prion Disease. New York: Springer Science+Business Media, Inc.; 2005:83-109.
132. Giasson BI, Duda JE, Quinn SM, et al. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 2002;34:521-533.
133. Giles K, Glidden DV, Beckwith R, et al. Resistance of bovine spongiform encephalopathy (BSE) prions to inactivation. PLoS Pathog 2008;4:e1000206.
134. Giles K, Glidden DV, Patel S, et al. Human prion strain selection in transgenic mice. Ann Neurol 2010;68:151-161.
135. Giri RK, Young RY, Pitstick R, et al. Prion infection of mouse neurospheres. Proc Natl Acad Sci U S A 2006;103:3875-3880.
136. Glatzel M, Abela E, Maissen M, et al. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003;349:1812-1820.
137. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984;122:1131-1135.
138. Goate A, Chartier-Harlin M-C, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-706.
139. Goldfarb LG, Brown P, Mitrova E, et al. Creutzfeldt-Jacob disease associated with the PRNP codon 200Lys mutation: an analysis of 45 families. Eur J Epidemiol 1991;7:477-486.
140. Goldfarb LG, Korczyn AD, Brown P, et al. Mutation in codon 200 of scrapie amyloid precursor gene linked to Creutzfeldt-Jakob disease in Sephardic Jews of Libyan and non-Libyan origin. Lancet 1990;336:637-638.
141. Goldmann W, Hunter N, Manson J, et al. Presented at the Proceedings of the VIIIth International Congress of Virology, Berlin. 26-31, 1990.
142. Goldmann W, Hunter N, Martin T, et al. Different forms of the bovine PrP gene have five or six copies of a short, G-C-rich element within the protein-coding exon. J Gen Virol 1991;72:201-204.
143. Goldmann W, Hunter N, Smith G, et al. PrP genotype and agent effects in scrapie: change in allelic interaction with different isolates of agent in sheep, a natural host of scrapie. J Gen Virol 1994;75:989-995.
144. Gorodinsky A, Harris DA. Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin. J Cell Biol 1995;129:619-627.
145. Gossert AD, Bonjour S, Lysek DA, et al. Prion protein NMR structures of elk and of mouse/elk hybrids. Proc Natl Acad Sci U S A 2005;102:646-650.
146. Govaerts C, Wille H, Prusiner SB, et al. Evidence for assembly of prions with left-handed β-helices into trimers. Proc Natl Acad Sci U S A 2004;101:8342-8347.
147. Greenwald J, Buhtz C, Ritter C, et al. The mechanism of prion inhibition by HET-S. Mol Cell 2010;38:889-899.
148. Grundke-Iqbal I, Iqbal K, Tung Y-C, et al. Abnormal phosphorylation of the microtubule-associated protein (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 1986;83:4913-4917.
149. Guo JL, Lee VM-Y. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 2011;286:15317-15331.
150. Haass C, Lemere CA, Capell A, et al. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med 1995;1:1291-1296.
151. Haire LF, Whyte SM, Vasisht N, et al. The crystal structure of the globular domain of sheep prion protein. J Mol Biol 2004;336:1175-1183.
152. Haley NJ, Seelig DM, Zabel MD, et al. Detection of CWD prions in urine and saliva of deer by transgenic mouse bioassay. PLoS One 2009;4:e4848.
153. Hamir AN, Cutlip RC, Miller JM, et al. Preliminary findings on the experimental transmission of chronic wasting disease agent of mule deer to cattle. J Vet Diagn Invest 2001;13:91-96.
154. Hegde RS, Mastrianni JA, Scott MR, et al. A transmembrane form of the prion protein in neurodegenerative disease. Science 1998;279:827-834.
155. Heikenwalder M, Zeller N, Seeger H, et al. Chronic lymphocytic inflammation specifies the organ tropism of prions. Science 2005;307:1107-1110.
156. Heppner FL, Musahl C, Arrighi I, et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 2001;294:178-182.
157. Hetz C, Russelakis-Carneiro M, Maundrell K, et al. Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J 2003;22:5435-5445.
158. Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997;389:448-450.
159. Hilton DA, Ghani AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004;203:733-739.
160. Hornemann S, Schorn C, Wuthrich K. NMR structure of the bovine prion protein isolated from healthy calf brains. EMBO Rep 2004;5:1159-1164.
161. Hornshaw MP, McDermott JR, Candy JM, et al. Copper binding to the N-terminal tandem repeat region of mammalian and avian prion protein: structural studies using synthetic peptides. Biochem Biophys Res Commun 1995;214:993-999.
162. Hou F, Sun L, Zheng H, et al. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 2011;146:448-461.
163. Houston F, Goldmann W, Chong A, et al. Prion diseases: BSE in sheep bred for resistance to infection. Nature 2003;423:498.
164. Hsiao K, Baker HF, Crow TJ, et al. Linkage of a prion protein missense variant to Gerstmann-Sträussler syndrome. Nature 1989;338:342-345.
165. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
166. Hsiao K, Meiner Z, Kahana E, et al. Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N Engl J Med 1991;324:1091-1097.
167. Hunter N, Foster JD, Benson G, et al. Restriction fragment length polymorphisms of the scrapie-associated fibril protein (PrP) gene and their association with susceptiblity to natural scrapie in British sheep. J Gen Virol 1991;72:1287-1292.
168. Hunter N, Goldmann W, Smith G, et al. Frequencies of PrP gene variants in healthy cattle and cattle with BSE in Scotland. Vet Rec 1994;135:400-403.
169. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-705.
170. Ilc G, Giachin G, Jaremko M, et al. NMR structure of the human prion protein with the pathological Q212P mutation reveals unique structural features. PLoS One 2010;5:e11715.
171. Ironside JW. The new variant form of Creutzfeldt-Jakob disease: a novel prion protein amyloid disorder (Editorial). Amyloid 1997;4:66-69.
172. Ishikura N, Clever JL, Bouzamondo-Bernstein E, et al. Notch-1 activation and dendritic atrophy in prion disease. Proc Natl Acad Sci U S A 2005;102:886-891.
173. Jackson GS, McKintosh E, Flechsig E, et al. An enzyme-detergent method for effective prion decontamination of surgical steel. J Gen Virol 2005;86:869-878.
174. Jackson WS, Borkowski AW, Faas H, et al. Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice. Neuron 2009;63:438-450.
175. James TL, Liu H, Ulyanov NB, et al. Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. Proc Natl Acad Sci U S A 1997;94:10086-10091.
176. Jansen C, Parchi P, Capellari S, et al. Prion protein amyloidosis with divergent phenotype associated with two novel nonsense mutations in PRNP. Acta Neuropathol 2010;119:189-197.
177. Jarrett JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993;73:1055-1058.
178. Jendroska K, Heinzel FP, Torchia M, et al. Proteinase-resistant prion protein accumulation in Syrian hamster brain correlates with regional pathology and scrapie infectivity. Neurology 1991;41:1482-1490.
179. Jin M, Shepardson N, Yang T, et al. Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 2011;108:5819-5824.
180. Johan K, Westermark G, Engstrom U, et al. Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. Proc Natl Acad Sci U S A 1998;95:2558-2563.
181. Johnson BS, Snead D, Lee JJ, et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 2009;284:20329-20339.
182. Kahana E, Milton A, Braham J, et al. Creutzfeldt-Jakob disease: focus among Libyan Jews in Israel. Science 1974;183:90-91.
183. Kaimann T, Metzger S, Kuhlmann K, et al. Molecular model of an alpha-helical prion protein dimer and its monomeric subunits as derived from chemical cross-linking and molecular modeling calculations. J Mol Biol 2008;376:582-596.
184. Kajava AV, Baxa U, Steven AC. Beta arcades: recurring motifs in naturally occurring and disease-related amyloid fibrils. FASEB J 2010;24:1311-1319.
185. Kanaani J, Prusiner SB, Diacovo J, et al. Recombinant prion protein induces rapid polarization and development of synapses in embryonic rat hippocampal neurons in vitro. J Neurochem 2005;95:1373-1386.
186. Kaneko K, Ball HL, Wille H, et al. A synthetic peptide initiates Gerstmann-Sträussler-Scheinker (GSS) disease in transgenic mice. J Mol Biol 2000;295:997-1007.
187. Kaneko K, Zulianello L, Scott M, et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci U S A 1997;94:10069-10074.
188. Kanyo ZF, Pan K-M, Williamson A, et al. Antibody binding defines a structure for an epitope that participates in the PrPC-> PrPSc conformational change. J Mol Biol 1999;293:855-863.
189. Kawasaki Y, Kawagoe K, Chen CJ, et al. Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. J Virol 2007;81:12889-12898.
190. Khan MQ, Sweeting B, Mulligan VK, et al. Prion disease susceptibility is affected by beta-structure folding propensity and local side-chain interactions in PrP. Proc Natl Acad Sci U S A 2010;107:19808-19813.
191. Kiachopoulos S, Bracher A, Winklhofer KF, et al. Pathogenic mutations located in the hydrophobic core of the prion protein interfere with folding and attachment of the glycosylphosphatidylinositol anchor. J Biol Chem 2005;280:9320-9329.
192. Kimberlin R, Walker C. Characteristics of a short incubation model of scrapie in the golden hamster. J Gen Virol 1977;34:295-304.
193. Kimberlin RH, Walker CA. The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection. Arch Virol 1983;78:9-18.
194. Kimberlin RH, Walker CA, Fraser H. The genomic identity of different strains of mouse scrapie is expressed in hamsters and preserved on reisolation in mice. J Gen Virol 1989;70:2017-2025.
195. King CY, Diaz-Avalos R. Protein-only transmission of three yeast prion strains. Nature 2004;428:319-323.
196. Kitamoto T, Muramoto T, Mohri S, et al. Abnormal isoform of prion protein accumulates in follicular dendritic cells in mice with Creutzfeldt-Jakob disease. J Virol 1991;65:6292-6295.
197. Kitamoto T, Tateishi J. Human prion diseases with variant prion protein. Philos Trans R Soc Lond B Biol Sci 1994;343:391-398.
198. Klitzman RL, Alpers MP, Gajdusek DC. The natural incubation period of kuru and the episodes of transmission in three clusters of patients. Neuroepidemiology 1984;3:3-20.
199. Knaus KJ, Morillas M, Swietnicki W, et al. Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nat Struct Biol 2001;8:770-774.
200. Kocisko DA, Vaillant A, Lee KS, et al. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob Agents Chemother 2006;50:1034-1044.
201. Kong C, Ito K, Walsh MA, et al. Crystal structure and functional analysis of the eukaryotic class II release factor eRF3 from S. pombe. Mol Cell 2004;14:233-245.
202. Kong Q, Huang S, Zou W, et al. Chronic wasting disease of elk: transmissibility to humans examined by transgenic mouse models. J Neurosci 2005;25:7944-7999.
203. Kong Q, Surewicz WK, Petersen RB, et al. Inherited prion diseases. In: Prusiner SB, ed. Prion Biology and Diseases. 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2004:673-775.
204. Korth C, Kaneko K, Groth D, et al. Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene. Proc Natl Acad Sci U S A 2003;100:4784-4789.
205. Korth C, May BCH, Cohen FE, et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 2001;98:9836-9841.
206. Korth C, Stierli B, Streit P, et al. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature 1997;389:74-77.
207. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 1986;83:4044-4048.
208. Kozin SA, Bertho G, Mazur AK, et al. Sheep prion protein synthetic peptide spanning helix 1 and beta-strand 2 (residues 142-166) shows beta-hairpin structure in solution. J Biol Chem 2001;276:46364-46370.
209. Kretzschmar HA, Neumann M, Stavrou D. Codon 178 mutation of the human prion protein gene in a German family (Backer family): sequencing data from 72 year-old celloidin-embedded brain tissue. Acta Neuropathol 1995;89:96-98.
210. Kretzschmar HA, Prusiner SB, Stowring LE, et al. Scrapie prion proteins are synthesized in neurons. Am J Pathol 1986;122:1-5.
211. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998;95:6448-6453.
212. Laplanche J-L, Chatelain J, Beaudry P, et al. French autochthonous scrapied sheep without the 136Val PrP polymorphism. Mamm Genome 1993;4:463-464.
213. Laplanche J-L, Chatelain J, Launay J-M, et al. Deletion in prion protein gene in a Moroccan family. Nucleic Acids Res 1990;18:6745.
214. Lasmézas CI, Deslys J-P, Demaimay R, et al. BSE transmission to macaques. Nature 1996;381:743-744.
215. Latarjet R, Muel B, Haig DA, et al. Inactivation of the scrapie agent by near monochromatic ultraviolet light. Nature 1970;227:1341-1343.
216. Lee H-J, Suk J-E, Bae E-J, et al. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol 2008;40:1835-1849.
217. Lee IS, Long JR, Prusiner SB, et al. Selective precipitation of prions by polyoxometalate complexes. J Am Chem Soc 2005;127:13802-13803.
218. Lee S, Antony L, Hartmann R, et al. Conformational diversity in prion protein variants influences intermolecular beta-sheet formation. EMBO J 2010;29:251-262.
219. Lee VM-Y, Balin BJ, Orvos IJ, et al. A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science 1991;251:645-678.
220. Legname G, Baskakov IV, Nguyen H-OB, et al. Synthetic mammalian prions. Science 2004;305:673-676.
221. Legname G, Nguyen H-OB, Baskakov IV, et al. Strain-specified characteristics of mouse synthetic prions. Proc Natl Acad Sci U S A 2005;102:2168-2173.
222. Legname G, Nguyen H-OB, Peretz D, et al. Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc Natl Acad Sci U S A 2006;103:19105-19110.
223. Liu H, Farr-Jones S, Ulyanov NB, et al. Solution structure of Syrian hamster prion protein rPrP(90-231). Biochemistry 1999;38:5362-5377.
224. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363:417-421.
225. López García F, Zahn R, Riek R, et al. NMR structure of the bovine prion protein. Proc Natl Acad Sci U S A 2000;97:8334-8339.
226. Luginbuhl B, Kanyo Z, Jones RM, et al. Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation. J Mol Biol 2006;363:75-97.
227. Lührs T, Riek R, Guntert P, et al. NMR structure of the human doppel protein. J Mol Biol 2003;326:1549-1557.
228. Lysek DA, Schorn C, Nivon LG, et al. Prion protein NMR structures of cats, dogs, pigs, and sheep. Proc Natl Acad Sci U S A 2005;102:640-645.
229. Ma J, Lindquist S. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science 2002;298:1785-1788.
230. Maddelein ML, Dos Reis S, Duvezin-Caubet S, et al. Amyloid aggregates of the HET-s prion protein are infectious. Proc Natl Acad Sci U S A 2002;99:7402-7407.
231. Makarava N, Kovacs GG, Bocharova O, et al. Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol 2010;119:177-187.
232. Málaga-Trillo E, Solis GP, Schrock Y, et al. Regulation of embryonic cell adhesion by the prion protein. PLoS Biol 2009;7:e55.
233. Mallucci G, Dickinson A, Linehan J, et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003;302:871-874.
234. Mallucci GR, Ratte S, Asante EA, et al. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J 2002;21:202-210.
235. Mallucci GR, White MD, Farmer M, et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 2007;53:325-335.
236. Manson JC, Clarke AR, Hooper ML, et al. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol Neurobiol 1994;8:121-127.
237. Manuelidis L, Tesin DM, Sklaviadis T, et al. Astrocyte gene expression in Creutzfeldt-Jakob disease. Proc Natl Acad Sci U S A 1987;84:5937-5941.
238. Mark G, Tauber A, Laupert R, et al. OH-radical formation by ultrasound in aqueous solution-Part II: Terephthalate and Fricke dosimetry and the influence of various conditions on the sonolytic yield. Ultrason Sonochem 1998;5:41-52.
239. Marsh RF, Bessen RA, Lehmann S, et al. Epidemiological and experimental studies on a new incident of transmissible mink encephalopathy. J Gen Virol 1991;72:589-594.
240. Masters CL, Gajdusek DC, Gibbs CJ Jr. Creutzfeldt-Jakob disease virus isolations from the Gerstmann-Sträussler syndrome. Brain 1981;104:559-588.
241. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985;82:4245-4249.
242. Mathiason CK, Powers JG, Dahmes SJ, et al. Infectious prions in the saliva and blood of deer with chronic wasting disease. Science 2006;314:133-136.
243. May BCH, Fafarman AT, Hong SB, et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc Natl Acad Sci U S A 2003;100:3416-3421.
244. May BCH, Govaerts C, Prusiner SB, et al. Prions: so many fibers, so little infectivity. Trends Biochem Sci 2004;29:162-165.
245. McKee AC, Cantu RC, Nowinski CJ, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 2009;68:709-735.
246. McKinley MP, Bolton DC, Prusiner SB. A protease-resistant protein is a structural component of the scrapie prion. Cell 1983;35:57-62.
247. McKinley MP, Braunfeld MB, Bellinger CG, et al. Molecular characteristics of prion rods purified from scrapie-infected hamster brains. J Infect Dis 1986;154:110-120.
248. McKinley MP, Meyer RK, Kenaga L, et al. Scrapie prion rod formation in vitro requires both detergent extraction and limited proteolysis. J Virol 1991;65:1340-1351.
249. Mead S. Prion disease genetics. Eur J Hum Genet 2006;14:273-281.
250. Megy S, Bertho G, Kozin SA, et al. Possible role of region 152-156 in the structural duality of a peptide fragment from sheep prion protein. Protein Sci 2004;13:3151-3160.
251. Meier P, Genoud N, Prinz M, et al. Soluble dimeric prion protein binds PrPSc in vivo and antagonizes prion disease. Cell 2003;113:49-60.
252. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006;313:1781-1784.
253. Miele G, Manson J, Clinton M. A novel erythroid-specific marker of transmissible spongiform encephalopathies. Nat Med 2001;7:361-364.
254. Miller MW, Williams ES, McCarty CW, et al. Epizootiology of chronic wasting disease in free-ranging cervids in Colorado and Wyoming. J Wildl Dis 2000;36:676-690.
255. Mills JL, Schonberger LB, Wysowski DK, et al. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr 2004;144:430-436.
256. Millson GC, Hunter GD, Kimberlin RH. The physico-chemical nature of the scrapie agent. In: Kimberlin RH, ed. Slow Virus Diseases of Animals and Man. New York: American Elsevier; 1976:243-266.
257. Minor P, Newham J, Jones N, et al. Standards for the assay of Creutz{reversed not sign}feldt-Jakob disease specimens. J Gen Virol 2004;85:1777-1784.
258. Mishra RS, Gu Y, Bose S, et al. Cell surface accumulation of a truncated transmembrane prion protein in Gerstmann-Straussler-Scheinker disease P102L. J Biol Chem 2002;277:24554-24561.
259. Mo H, Moore RC, Cohen FE, et al. Two different neurodegenerative diseases caused by proteins with similar structures. Proc Natl Acad Sci U S A 2001;98:2352-2357.
260. Moore RC, Hope J, McBride PA, et al. Mice with gene targetted prion protein alterations show that Prnp, Sinc and Prni are congruent. Nat Genet 1998;18:118-125.
261. Moore RC, Lee IY, Silverman GL, et al. Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. J Mol Biol 1999;292:797-817.
262. Moore RC, Mastrangelo P, Bouzamondo E, et al. Doppel-induced cerebellar degeneration in transgenic mice. Proc Natl Acad Sci U S A 2001;98:15288-15293.
263. Morales R, Duran-Aniotz C, Castilla J, et al. De novo induction of amyloid-β deposition in vivo. Mol Psychiatry 2012;17(12)1347-1353.
264. Mougenot AL, Nicot S, Bencsik A, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 2012;33(9):2225-2228.
265. Mouillet-Richard S, Ermonval M, Chebassier C, et al. Signal transduction through prion protein. Science 2000;289:1925-1928.
266. Münch C, O'Brien J, Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci U S A 2011;108:3548-3553.
267. Muramoto T, DeArmond SJ, Scott M, et al. Heritable disorder resembling neuronal storage disease in mice expressing prion protein with deletion of an α-helix. Nat Med 1997;3:750-755.
268. Nazor KE, Kuhn F, Seward T, et al. Immunodetection of disease-associated mutant PrP, which accelerates disease in GSS transgenic mice. EMBO J 2005;24:2472-2480.
269. Nelson R, Sawaya MR, Balbirnie M, et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature 2005;435:773-778.
270. Nichols TA, Pulford B, Wyckoff AC, et al. Detection of protease-resistant cervid prion protein in water from a CWD-endemic area. Prion 2009;3:171-183.
271. Nishina K, Deleault NR, Lucassen RW, et al. In vitro prion protein conversion in detergent-solubilized membranes. Biochemistry 2004;43:2613-2621.
272. Nishina KA, Deleault NR, Mahal SP, et al. The stoichiometry of host PrPC glycoforms modulates the efficiency of PrPSc formation in vitro. Biochemistry 2006;45:14129-14139.
273. O'Rourke KI, Holyoak GR, Clark WW, et al. PrP genotypes and experimental scrapie in orally inoculated Suffolk sheep in the United States. J Gen Virol 1997;78:975-978.
274. Oesch B, Westaway D, Wälchli M, et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell 1985;40:735-746.
275. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A 2009;106:12571-12572.
276. Omalu B, Hammers JL, Bailes J, et al. Chronic traumatic encephalopathy in an Iraqi war veteran with posttraumatic stress disorder who committed suicide. Neurosurg Focus 2011;31:E3.
277. Omalu BI, DeKosky ST, Minster RL, et al. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery 2005;57:128-134.
278. Paisley D, Banks S, Selfridge J, et al. Male infertility and DNA damage in Doppel knockout and prion protein/Doppel double-knockout mice. Am J Pathol 2004;164:2279-2288.
279. Palmer MS, Dryden AJ, Hughes JT, et al. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 1991;352:340-342.
280. Pan K-M, Baldwin M, Nguyen J, et al. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A 1993;90:10962-10966.
281. Papadopoulos E, Oglecka K, Maler L, et al. NMR solution structure of the peptide fragment 1-30, derived from unprocessed mouse Doppel protein, in DHPC micelles. Biochemistry 2006;45:159-166.
282. Parchi P, Capellari S, Chen SG, et al. Typing prion isoforms. Nature 1997;386:232-233.
283. Parry HB. Scrapie disease in sheep. New York: Academic Press; 1983.
284. Parry HB. Scrapie: a transmissible and hereditary disease of sheep. Heredity 1962;17:75-105.
285. Pattison IH. Experiments with scrapie with special reference to the nature of the agent and the pathology of the disease. In: Gajdusek DC, Gibbs CJ Jr, Alpers MP, eds. Slow, Latent and Temperate Virus Infections, NINDB Monograph 2. U.S. Washington, D.C: Government Printing; 1965:249-257.
286. Pattison IH, Jebbett JN. Clinical and histological observations on cuprizone toxicity and scrapie in mice. Res Vet Sci 1971;12:378-380.
287. Pattison IH, Millson GC. Scrapie produced experimentally in goats with special reference to the clinical syndrome. J Comp Pathol 1961;71:101-108.
288. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004;364:527-529.
289. Peretz D, Supattapone S, Giles K, et al. Inactivation of prions by acidic sodium dodecyl sulfate. J Virol 2006;80:322-331.
290. Peretz D, Williamson RA, Kaneko K, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001;412:739-743.
291. Peretz D, Williamson RA, Legname G, et al. A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron 2002;34:921-932.
292. Peretz D, Williamson RA, Matsunaga Y, et al. A conformational transition at the N-terminus of the prion protein features in formation of the scrapie isoform. J Mol Biol 1997;273:614-622.
293. Pérez DR, Damberger FF, Wüthrich K. Horse prion protein NMR structure and comparisons with related variants of the mouse prion protein. J Mol Biol 2010;400:121-128.
294. Perrier V, Kaneko K, Safar J, et al. Dominant-negative inhibition of prion replication in transgenic mice. Proc Natl Acad Sci U S A 2002;99:13079-13084.
295. Perrier V, Wallace AC, Kaneko K, et al. Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proc Natl Acad Sci U S A 2000;97:6073-6078.
296. Pfeifer A, Eigenbrod S, Al-Khadra S, et al. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest 2006;116:3204-3210.
297. Phillips NA, Bridgeman J, Ferguson-Smith M. Findings & Conclusions, The BSE Inquiry. vol. 1. London: Stationery Office; 2000.
298. Piening N, Weber P, Giese A, et al. Breakage of PrP aggregates is essential for efficient autocatalytic propagation of misfolded prion protein. Biochem Biophys Res Commun 2005;326:339-343.
299. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
300. Poncet-Montange G, St.-Martin SJ, Bogatova OV, et al. A survey of antiprion compounds reveals the prevalence of non-PrP molecular targets. J Biol Chem 2011;286:27718-27728.
301. Post K, Brown DR, Groschup M, et al. Neurotoxicity but not infectivity of prion proteins can be induced reversibly in vitro. Arch Virol Suppl 2000;(16):265-273.
302. Poulter M, Baker HF, Frith CD, et al. Inherited prion disease with 144 base pair gene insertion. 1. Genealogical and molecular studies. Brain 1992;115:675-685.
303. Premzl M, Sangiorgio L, Strumbo B, et al. Shadoo, a new protein highly conserved from fish to mammals and with similarity to prion protein. Gene 2003;314:89-102.
304. Priola SA, Raines A, Caughey WS. Porphyrin and phthalocyanine antiscrapie compounds. Science 2000;287:1503-1506.
305. Proske D, Gilch S, Wopfner F, et al. Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem 2002;3:717-725.
306. Prusiner SB. Detecting mad cow disease. Sci Am 2004;291:86-93.
307. Prusiner SB. Molecular biology of prion diseases. Science 1991;252:1515-1522.
308. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982;216:136-144.
309. Prusiner SB. Prion diseases and the BSE crisis. Science 1997;278:245-251.
310. Prusiner SB. Shattuck Lecture-Neurodegenerative diseases and prions. N Engl J Med 2001;344:1516-1526.
311. Prusiner SB. Some speculations about prions, amyloid, and Alzheimer's disease. N Engl J Med 1984;310:661-663.
312. Prusiner SB, Groth D, Serban A, et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci U S A 1993;90:10608-10612.
313. Prusiner SB, Hadlow WJ, Garfin DE, et al. Partial purification and evidence for multiple molecular forms of the scrapie agent. Biochemistry 1978;17:4993-4997.
314. Prusiner SB, McKinley MP, Bolton DC, et al. Prions: methods for assay, purification and characterization. In: Maramorosch K, Koprowski H, eds. Methods in Virology. vol. 8. New York: Academic Press; 1984:293-345.
315. Prusiner SB, McKinley MP, Bowman KA, et al. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 1983;35:349-358.
316. Prusiner SB, Scott M, Foster D, et al. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 1990;63:673-686.
317. Race RE, Raymond GJ. Inactivation of transmissible spongiform encephalopathy (prion) agents by environ LpH. J Virol 2004;78:2164-2165.
318. Raeber AJ, Sailer A, Hegyi I, et al. Ectopic expression of prion protein (PrP) in T lymphocytes or hepatocytes of PrP knockout mice is insufficient to sustain prion replication. Proc Natl Acad Sci U S A 1999;96:3987-3992.
319. Redmond L, Oh SR, Hicks C, et al. Nuclear Notch1 signaling and the regulation of dendritic development. Nat Neurosci 2000;3:30-40.
320. Ren PH, Lauckner JE, Kachirskaia I, et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 2009;11:219-225.
321. Requena JR, Groth D, Legname G, et al. Copper-catalyzed oxidation of the recombinant SHa(29-231) prion protein. Proc Natl Acad Sci U S A 2001;98:7170-7175.
322. Rieger R, Edenhofer F, Lasmézas CI, et al. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med 1997;3:1383-1388.
323. Riek R, Hornemann S, Wider G, et al. NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). FEBS Lett 1997;413:282-288.
324. Riek R, Hornemann S, Wider G, et al. NMR structure of the mouse prion protein domain PrP(121-231). Nature 1996;382:180-182.
325. Rivera-Milla E, Oidtmann B, Panagiotidis CH, et al. Disparate evolution of prion protein domains and the distinct origin of Doppel-and prion-related loci revealed by fish-to-mammal comparisons. FASEB J 2006;20:317-319.
326. Rogers M, Yehiely F, Scott M, et al. Conversion of truncated and elongated prion proteins into the scrapie isoform in cultured cells. Proc Natl Acad Sci U S A 1993;90:3182-3186.
327. Ronga L, Palladino P, Saviano G, et al. Structural characterization of a neurotoxic threonine-rich peptide corresponding to the human prion protein alpha 2-helical 180-195 segment, and comparison with full-length alpha 2-helix-derived peptides. J Pept Sci 2008;14:1096-1102.
328. Roos R, Gajdusek DC, Gibbs CJ Jr. The clinical characteristics of transmissible Creutzfeldt-Jakob disease. Brain 1973;96:1-20.
329. Rossi D, Cozzio A, Flechsig E, et al. Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain. EMBO J 2001;20:694-702.
330. Ryou C, Legname G, Peretz D, et al. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab Invest 2003;83:837-843.
331. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001;411:810-813.
332. Saborío GP, Soto C, Kascsak RJ, et al. Cell-lysate conversion of prion protein into its protease-resistant isoform suggests the participation of a cellular chaperone. Biochem Biophys Res Commun 1999;258:470-475.
333. Safar J, Wille H, Itri V, et al. Eight prion strains have PrPSc molecules with different conformations. Nat Med 1998;4:1157-1165.
334. Safar JG, DeArmond SJ, Kociuba K, et al. Prion clearance in bigenic mice. J Gen Virol 2005;86:2913-2923.
335. Safar JG, Geschwind MD, Deering C, et al. Diagnosis of human prion disease. Proc Natl Acad Sci U S A 2005;102:3501-3506.
336. Safar JG, Kellings K, Serban A, et al. Search for a prion-specific nucleic acid. J Virol 2005;79:10796-10806.
337. Safar JG, Scott M, Monaghan J, et al. Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotechnol 2002;20:1147-1150.
338. Sakaguchi S, Katamine S, Nishida N, et al. Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene. Nature 1996;380:528-531.
339. Sales N, Hassig R, Rodolfo K, et al. Developmental expression of the cellular prion protein in elongating axons. Eur J Neurosci 2002;15:1163-1177.
340. Sandberg MK, Al-Doujaily H, Sharps B, et al. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 2011;470:540-542.
341. Santuccione A, Sytnyk V, Leshchyns'ka I, et al. Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth. J Cell Biol 2005;169:341-354.
342. Sawaya MR, Sambashivan S, Nelson R, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 2007;447:453-457.
343. Schmitt-Ulms G, Ehsani S, Watts JC, et al. Evolutionary descent of prion genes from the ZIP family of metal ion transporters. PLoS One 2009;4:e7208.
344. Schmitt-Ulms G, Hansen K, Liu J, et al. Time-controlled transcardiac perfusion cross-linking for the study of protein interactions in complex tissues. Nat Biotechnol 2004;22:724-731.
345. Schmitt-Ulms G, Legname G, Baldwin MA, et al. Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. J Mol Biol 2001;314:1209-1225.
346. Schneider B, Mutel V, Pietri M, et al. NADPH oxidase and extracellular regulated kinases 1/2 are targets of prion protein signaling in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A 2003;100:13326-13331.
347. Schütz AK, Soragni A, Hornemann S, et al. The amyloid-Congo red interface at atomic resolution. Angew Chem Int Ed Engl 2011;50:5956-5960.
348. Scott M, Foster D, Mirenda C, et al. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell 1989;59:847-857.
349. Scott MR, Groth D, Tatzelt J, et al. Propagation of prion strains through specific conformers of the prion protein. J Virol 1997;71:9032-9044.
350. Scott MR, Peretz D, Nguyen HO, et al. Transmission barriers for bovine, ovine, and human prions in transgenic mice. J Virol 2005;79:5259-5271.
351. Scott MR, Safar J, Telling G, et al. Identification of a prion protein epitope modulating transmission of bovine spongiform encephalopathy prions to transgenic mice. Proc Natl Acad Sci U S A 1997;94:14279-14284.
352. Scott MR, Will R, Ironside J, et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci U S A 1999;96:15137-15142.
353. Serban A, Legname G, Hansen K, et al. Immunoglobulins in urine of hamsters with scrapie. J Biol Chem 2004;279:48817-48820.
354. Serban D, Taraboulos A, DeArmond SJ, et al. Rapid detection of Creutzfeldt-Jakob disease and scrapie prion proteins. Neurology 1990;40:110-117.
355. Sethi S, Lipford G, Wagner H, et al. Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 2002;360:229-230.
356. Setlow RB. Shedding light on proteins, nucleic acids, cells, humans and fish. Mutat Res 2002;511:1-14.
357. Shaked GM, Shaked Y, Kariv-Inbal Z, et al. A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. J Biol Chem 2001;276:31479-31482.
358. Shikiya RA, Ayers JI, Schutt CR, et al. Coinfecting prion strains compete for a limiting cellular resource. J Virol 2010;84:5706-5714.
359. Shmerling D, Hegyi I, Fischer M, et al. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 1998;93:203-214.
360. Shorter J, Lindquist S. Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science 2004;304:1793-1797.
361. Si K, Choi YB, White-Grindley E, et al. Aplysia CPEB can form prion-like multimers in sensory neurons that contribute to long-term facilitation. Cell 2010;140:421-435.
362. Si K, Lindquist S, Kandel ER. A neuronal isoform of the aplysia CPEB has prion-like properties. Cell 2003;115:879-891.
363. Sigurdsson B. Rida, a chronic encephalitis of sheep with general remarks on infections which develop slowly and some of their special characteristics. Br Vet J 1954;110:341-354.
364. Sigurdsson EM, Sy MS, Li R, et al. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett 2003;336:185-187.
365. Silveira JR, Raymond GJ, Hughson AG, et al. The most infectious prion protein particles. Nature 2005;437:257-261.
366. Singleton AB, Farrer M, Johnson J, et al. α-Synuclein locus triplication causes Parkinson's disease. Science 2003;302:841.
367. Smirnovas V, Baron GS, Offerdahl DK, et al. Structural organization of brain-derived mammalian prions examined by hydrogen-deuterium exchange. Nat Struct Mol Biol 2011;18:504-506.
368. Solomon A, Richey T, Murphy CL, et al. Amyloidogenic potential of foie gras. Proc Natl Acad Sci U S A 2007;104:10998-11001.
369. Somerville RA, Chong A, Mulqueen OU, et al. Biochemical typing of scrapie strains. Nature 1997;386:564.
370. Sparkes RS, Simon M, Cohn VH, et al. Assignment of the human and mouse prion protein genes to homologous chromosomes. Proc Natl Acad Sci U S A 1986;83:7358-7362.
371. Sparrer HE, Santoso A, Szoka FC Jr, et al. Evidence for the prion hypothesis: induction of the yeast [PSI+] factor by in vitro-converted Sup35 protein. Science 2000;289:595-599.
372. Spudich S, Mastrianni JA, Wrensch M, et al. Complete penetrance of Creutzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Mol Med 1995;1:607-613.
373. Stahl N, Baldwin MA, Burlingame AL, et al. Identification of glycoinositol phospholipid linked and truncated forms of the scrapie prion protein. Biochemistry 1990;29:8879-8884.
374. Stahl N, Baldwin MA, Teplow DB, et al. Structural analysis of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry 1993;32:1991-2002.
375. Stahl N, Borchelt DR, Hsiao K, et al. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 1987;51:229-240.
376. Stathopulos PB, Scholz GA, Hwang YM, et al. Sonication of proteins causes formation of aggregates that resemble amyloid. Protein Sci 2004;13:3017-3027.
377. Stevens DJ, Walter ED, Rodriguez A, et al. Early onset prion disease from octarepeat expansion correlates with copper binding properties. PLoS Pathog 2009;5:e1000390.
378. Stewart RS, Harris DA. Mutational analysis of topological determinants in prion protein (PrP) and measurement of transmembrane and cytosolic PrP during prion infection. J Biol Chem 2003;278:45960-45968.
379. Stöckel J, Safar J, Wallace AC, et al. Prion protein selectively binds copper (II) ions. Biochemistry 1998;37:7185-7193.
380. Stöhr J, Watts JC, Legname G, et al. Spontaneous generation of anchorless prions in transgenic mice. Proc Natl Acad Sci U S A 2011;08(52):21223-21228.
381. Stuermer CA, Langhorst MF, Wiechers MF, et al. PrPC capping in T cells promotes its association with the lipid raft proteins reggie-1 and reggie-2 and leads to signal transduction. FASEB J 2004;18:1731-1733.
382. Sulkowski E. Purification of proteins by IMAC. Trends Biotechnol 1985;3:1-7.
383. Sung JY, Kim J, Paik SR, et al. Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. J Biol Chem 2001;276:27441-27448.
384. Supattapone S, Bosque P, Muramoto T, et al. Prion protein of 106 residues creates an artificial transmission barrier for prion replication in transgenic mice. Cell 1999;96:869-878.
385. Supattapone S, Bouzamondo E, Ball HL, et al. A protease-resistant 61-residue prion peptide causes neurodegeneration in transgenic mice. Mol Cell Biol 2001;21:2608-2616.
386. Supattapone S, Muramoto T, Legname G, et al. Identification of two prion protein regions that modify scrapie incubation time. J Virol 2001;75:1408-1413.
387. Supattapone S, Nguyen H-OB, Cohen FE, et al. Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci U S A 1999;96:14529-14534.
388. Supattapone S, Wille H, Uyechi L, et al. Branched polyamines cure prion-infected neuroblastoma cells. J Virol 2001;75:3453-3461.
389. Sydow A, Mandelkow EM. 'Prion-Like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy. Neurodegener Dis 2010;7:28-31.
390. Tamgüney G, Francis KP, Giles K, et al. Measuring prions by bioluminescence imaging. Proc Natl Acad Sci U S A 2009;106:15002-15006.
391. Tamgüney G, Giles K, Bouzamondo-Bernstein E, et al. Transmission of elk and deer prions to transgenic mice. J Virol 2006;80:9104-9114.
392. Tamgüney G, Miller MW, Wolfe LL, et al. Asymptomatic deer excrete infectious prions in faeces. Nature 2009;461:529-532.
393. Tamgüney G, Miller MW, Wolfe LL, et al. Corrigendum: Asymptomatic deer excrete infectious prions in faeces. Nature 2010;466:652.
394. Tamgüney G, Richt JA, Hamir AN, et al. Salivary prions in sheep and deer. Prion 2012;6(1):52-61.
395. Tanaka M, Chien P, Naber N, et al. Conformational variations in an infectious protein determine prion strain differences. Nature 2004;428:323-328.
396. Taraboulos A, Scott M, Semenov A, et al. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibits formation of the scrapie isoform. J Cell Biol 1995;129:121-132.
397. Tateishi J, Kitamoto T. Developments in diagnosis for prion diseases. Br Med Bull 1993;49:971-979.
398. Taubner LM, Bienkiewicz EA, Copie V, et al. Structure of the flexible amino-terminal domain of prion protein bound to a sulfated glycan. J Mol Biol 2010;395:475-490.
399. Taylor DR, Parkin ET, Cocklin SL, et al. Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. J Biol Chem 2009;284:22590-22600.
400. Telling GC, Haga T, Torchia M, et al. Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. Genes Dev 1996;10:1736-1750.
401. Telling GC, Parchi P, DeArmond SJ, et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 1996;274:2079-2082.
402. Telling GC, Scott M, Mastrianni J, et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 1995;83:79-90.
403. Tilly G, Chapuis J, Vilette D, et al. Efficient and specific down-regulation of prion protein expression by RNAi. Biochem Biophys Res Commun 2003;305:548-551.
404. Tobler I, Gaus SE, Deboer T, et al. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 1996;380:639-642.
405. Tremblay P, Ball HL, Kaneko K, et al. Mutant PrPSc conformers induced by a synthetic peptide and several prion strains. J Virol 2004;78:2088-2099.
406. Tremblay P, Meiner Z, Galou M, et al. Doxycyline control of prion protein transgene expression modulates prion disease in mice. Proc Natl Acad Sci U S A 1998;95:12580-12585.
407. Truant R, Atwal RS, Desmond C, et al. Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. FEBS J 2008;275:4252-4262.
408. Udan M, Baloh RH. Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion 2011;5:1-5.
409. Umland TC, Taylor KL, Rhee S, et al. The crystal structure of the nitrogen regulation fragment of the yeast prion protein Ure2p. Proc Natl Acad Sci U S A 2001;98:1459-1464.
410. van der Kamp MW, Daggett V. The consequences of pathogenic mutations to the human prion protein. Protein Eng Des Sel 2009;22:461-468.
411. Van Melckebeke H, Wasmer C, Lange A, et al. Atomic-resolution three-dimensional structure of HET-s(218-289) amyloid fibrils by solid-state NMR spectroscopy. J Am Chem Soc 2010;132:13765-13775.
412. Wadsworth JD, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001;358:171-180.
413. Wang F, Wang X, Yuan C-G, et al. Generating a prion with bacterially expressed recombinant prion protein. Science 2010;327:1132-1135.
414. Wang F, Yang F, Hu Y, et al. Lipid interaction converts prion protein to a PrPSc-like proteinase K-resistant conformation under physiological conditions. Biochemistry 2007;46:7045-7053.
415. Wasmer C, Lange A, Van Melckebeke H, et al. Amyloid fibrils of the HET-s(218-289) prion form a beta solenoid with a triangular hydrophobic core. Science 2008;319:1523-1526.
416. Watts JC, Giles K, Grillo SK, et al. Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A 2011;108:2528-2533.
417. Watts JC, Stöhr J, Bhardwaj S, et al. Protease-resistant prions selectively decrease Shadoo protein. PLoS Pathog 2011;7(11):e1002382.
418. Watts JC, Westaway D. The prion protein family: diversity, rivalry, and dysfunction. Biochim Biophys Acta 2007;1772:654-672.
419. Wells GA, Hawkins SA, Austin AR, et al. Studies of the transmissibility of the agent of bovine spongiform encephalopathy to pigs. J Gen Virol 2003;84:1021-1031.
420. Wells GAH. Report on TSE infectivity distribution in ruminant tissues (State of Knowledge, December 2001). European Commission 2002.
421. Wen Y, Li J, Xiong M, et al. Solution structure and dynamics of the I214V mutant of the rabbit prion protein. PLoS One 2010;5:e13273.
422. Wen Y, Li J, Yao W, et al. Unique structural characteristics of the rabbit prion protein. J Biol Chem 2010;285:31682-31693.
423. Westaway D, Zuliani V, Cooper CM, et al. Homozygosity for prion protein alleles encoding glutamine-171 renders sheep susceptible to natural scrapie. Genes Dev 1994;8:959-969.
424. Westermark GT, Westermark P. Prion-like aggregates: infectious agents in human disease. Trends Mol Med 2010;16:501-507.
425. White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003;422:80-83.
426. White MD, Farmer M, Mirabile I, et al. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci U S A 2008;105:10238-10243.
427. Wickner RB, Liebman SW, Saupe SJ. Prions of yeast and filamentous fungi: [URE3], [PSI+], [PIN+], and [Het-s]. In: Prusiner SB, ed. Prion Biology and Diseases. 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2004:305-372.
428. Wilesmith JW. The epidemiology of bovine spongiform encephalopathy. Semin Virol 1991;2:239-245.
429. Will RG, Alpers MP, Dormont D, et al. Infectious and sporadic prion diseases. In: Prusiner SB, ed. Prion Biology and Diseases. 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2004:629-671.
430. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-925.
431. Wille H, Bian W, McDonald M, et al. Natural and synthetic prion structure from X-ray fiber diffraction. Proc Natl Acad Sci U S A 2009;106:16990-16995.
432. Wille H, Govaerts C, Borovinskiy A, et al. Electron crystallography of the scrapie prion protein complexed with heavy metals. Arch Biochem Biophys 2007;467:239-248.
433. Wille H, Michelitsch MD, Guénebaut V, et al. Structural studies of the scrapie prion protein by electron crystallography. Proc Natl Acad Sci U S A 2002;99:3563-3568.
434. Wille H, Shanmugam M, Murugesu M, et al. Surface charge of polyoxometalates modulates polymerization of the scrapie prion protein. Proc Natl Acad Sci U S A 2009;106:3740-3745.
435. Williams ES, Miller MW. Chronic wasting disease in deer and elk in North America. Rev Sci Tech 2002;21:305-316.
436. Williams ES, Young S. Chronic wasting disease of captive mule deer: a spongiform encephalopathy. J Wildl Dis 1980;16:89-98.
437. Wiltzius JJ, Landau M, Nelson R, et al. Molecular mechanisms for protein-encoded inheritance. Nat Struct Mol Biol 2009;16:973-978.
438. Wood JG, Mirra SS, Pollock NJ, et al. Neurofibrillary tangles of Alzheimer's disease share antigenic determinants with the axonal microtubule-associated protein tau. Proc Natl Acad Sci U S A 1986;83:4040-4043.
439. Xing Y, Nakamura A, Chiba T, et al. Transmission of mouse senile amyloidosis. Lab Invest 2001;81:493-499.
440. Xing Y, Nakamura A, Korenaga T, et al. Induction of protein conformational change in mouse senile amyloidosis. J Biol Chem 2002;277:33164-33169.
441. Xu L, Aha P, Gu K, et al. Directed evolution of high-affinity antibody mimics using mRNA display. Chem Biol 2002;9:933-942.
442. Yamakawa Y, Hagiwara K, Nohtomi K, et al. Atypical proteinase K-resistant prion protein (PrPres) observed in an apparently healthy 23-month-old Holstein steer. Jpn J Infect Dis 2003;56:221-222.
443. Yoshida H, Matsushima N, Kumaki Y, et al. NMR studies of model peptides of PHGGGWGQ repeats within the N-terminus of prion proteins: a loop conformation with histidine and tryptophan in close proximity. J Biochem (Tokyo) 2000;128:271-281.
444. Yu X, Malenka RC. Beta-catenin is critical for dendritic morphogenesis. Nat Neurosci 2003;6:1169-1177.
445. Yung L, Huang Y, Lessard P, et al. Pharmacokinetics of quinacrine in the treatment of prion disease. BMC Infect Dis 2004;4:53-59.
446. Zahn R. The octapeptide repeats in mammalian prion protein constitute a pH-dependent folding and aggregation site. J Mol Biol 2003;334:477-488.
447. Zahn R, Guntert P, von Schroetter C, et al. NMR structure of a variant human prion protein with two disulfide bridges. J Mol Biol 2003;326:225-234.
448. Zahn R, Liu A, Lührs T, et al. NMR solution structure of the human prion protein. Proc Natl Acad Sci U S A 2000;97:145-150.
449. Zhang Y, Swietnicki W, Zagorski MG, et al. Solution structure of the E200K variant of human prion protein. Implications for the mechanism of pathogenesis in familial prion diseases. J Biol Chem 2000;275:33650-33654.
450. Zhu H, Bilgin M, Bangham R, et al. Global analysis of protein activities using proteome chips. Science 2001;293:2101-2105.
451. Zhu L, Ramboz S, Hewitt D, et al. Non-invasive imaging of GFAP expression after neuronal damage in mice. Neurosci Lett 2004;367:210-212.
452. Zobeley E, Flechsig E, Cozzio A, et al. Infectivity of scrapie prions bound to a stainless steel surface. Mol Med 1999;5:240-243.